Abstract Library

#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood

Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Oberg K

Authors: Öberg K, Califano A, Strosberg J, Ma S, Pape U,

Keywords: NETest, Meta-analysis, biomarker, in vitro diagnostic, diagnostic, management, NET, AUC, ROC,

#2754 Somatostatin Analogs (SSA) in Patients with Symptomatic Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)

Introduction: DIPNECH is characterized by a proliferation of pulmonary neuroendocrine cells and multifocal neuroendocrine tumorlets and/or tumors. Although usually indolent, DIPNECH can cause chronic cough and dyspnea. There is very limited information on treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Al-Toubah T, Strosberg J, Halfdanarson T, Oleinikov K, Gross D,

Keywords: DIPNECH, Somatostatin analogs, Octreotide, Lanreotide,

#2753 Risk of PRRT-Associated Bowel Obstruction in Patients with Mesenteric/Peritoneal Disease and Potential Role of Corticosteroids in Treatment

Introduction: Although radiation-induced mesenteritis or peritonitis can potentially exacerbate risk of bowel obstruction, there are no data in the literature on incidence of intestinal obstruction related to peptide receptor radiotherapy (PRRT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Al-Toubah T, El-Haddad G, Pelle E, Strosberg J,

Keywords: PRRT, Lutetium-dotatate, Bowel obstruction, Peritoneal carcinomatosis, Steroids,

#2161 Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Strosberg J

Authors: Al-Toubah T, Cives M, Anaya D, Soares H, Strosberg J,

Keywords: GEP-NET, locoregional treatment, ablation, embolization, surgical resection, neuroendocrine tumor, systemic therapy, external beam radiation,

#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,

Keywords: PDR001, immunotherapy, NET,